Francesco Bianchi Sells 1,250 Shares of LivaNova PLC (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

LivaNova Trading Down 1.2 %

Shares of NASDAQ:LIVN traded down $0.61 during trading on Friday, reaching $51.50. The stock had a trading volume of 515,183 shares, compared to its average volume of 609,560. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47. The firm’s fifty day moving average is $52.02 and its 200 day moving average is $51.60. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 123.19 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Mizuho cut their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $69.17.

Institutional Trading of LivaNova

Institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp grew its position in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the period. Canada Pension Plan Investment Board acquired a new stake in LivaNova in the second quarter worth $88,000. Central Pacific Bank Trust Division bought a new stake in LivaNova in the third quarter valued at $178,000. TradeLink Capital LLC acquired a new position in shares of LivaNova during the second quarter valued at about $208,000. Finally, Captrust Financial Advisors bought a new position in shares of LivaNova during the 3rd quarter worth about $217,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.